No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.3x · 10Y median 15.4x · 2nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:38:45.283Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for TScan Therapeutics, Inc. (TCRX) stock was $0.27 as of Oct 6, 2026, 2:30 PM EDT, down 8.33% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -85.9% · 3-year avg -54.4%/yr · 5-year avg -48.9%/yr
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Biotechnology · Waltham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.18
Revenue Est.
$459000.00
Last Quarter Results
EPS
$-0.23
vs Estimate
$-0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TCRX | $16.53M | $0.27 | -8.33% | -85.87% | -48.85% | N/A | N/A |
| 2DYAI | $16.70M | $0.46 | +0.93% | -60.69% | -38.53% | -11.56% | vs TCRX |
| 3BNGO | $16.75M | $1.46 | +1.04% | -24.38% | -78.37% | N/A | vs TCRX |
| 4MRKR | $17.01M | $1.02 | -3.77% | +11.06% | -42.13% | -33.25% | vs TCRX |
| 5LPCN | $17.11M | $2.08 | +0.24% | -38.07% | -34.76% | -29.99% | vs TCRX |
| 6PTN | $17.14M | $9.63 | +1.64% | +20.66% | -55.41% | -35.08% | vs TCRX |
forward FY estimate
N/A
$1.05M
vs Estimate
$1.88M
Consensus Rating
Based on 2 analysts
Average Price Target
$1.00
+269.4% upside
Low
$1.00
Current
$0.27
High
$1.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.25 | $-0.19 | $-0.08 | 3 |
| Quarter ending Dec 2026 | $-0.22 | $-0.15 | $-0.09 | 3 |
| Quarter ending Mar 2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Quarter ending Jun 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.90 | $-0.80 | $-0.62 | 3 |
| FY 2027 | $-0.95 | $-0.60 | $-0.25 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $459000.00 | $459000.00 | $459000.00 | 2 |
| Quarter ending Dec 2026 | $929250.00 | $929250.00 | $929250.00 | 2 |
| Quarter ending Mar 2027 | $937500.00 | $937500.00 | $937500.00 | 1 |
| Quarter ending Jun 2027 | $937500.00 | $937500.00 | $937500.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.64M | $2.91M | $3.54M | 3 |
| FY 2027 | $1.13M | $1.25M | $1.52M | 3 |
